NeuroOne Medical Technologies Corporation, trading on NASDAQ under the symbol NMTC, has scheduled the release of its financial results for the fiscal fourth quarter and year ended September 30, 2025. The announcement will occur before the market opens on Wednesday, December 17, 2025. Following the release, company management will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial outcomes and provide a corporate update, concluding with a question-and-answer session for telephone participants.
The company, which focuses on improving surgical care for patients with neurological disorders, is developing minimally invasive and high-definition solutions for electroencephalogram (EEG) recording, stimulation, and ablation. These technologies target conditions such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain from failed back surgeries. NeuroOne's work aims to enhance patient outcomes while potentially reducing procedural costs, positioning it at the intersection of medical technology and neurological healthcare.
For business and technology leaders, NeuroOne's financial results offer insights into the commercial viability and growth trajectory of innovative medical technologies. The company's focus on neurological disorders addresses a significant healthcare burden, with implications for both patient care and economic efficiency in medical procedures. As NeuroOne explores applications in areas like depression, mood disorders, and artificial intelligence, its progress could signal broader trends in the integration of advanced technology into healthcare solutions.
Investors and industry observers can access the conference call via telephone or webcast. The U.S. dial-in number is 888-506-0062, and the international dial-in is 973-528-0011, with participant access code 924910. The webcast will be available at https://www.webcaster4.com/Webcast/Page/2914/53302. A replay of the call will be accessible through December 31, 2025, by calling 877-481-4010 in the United States or 919-882-2331 internationally, using replay passcode 53302, or via the webcast link.
NeuroOne's developments are part of a larger trend in which technology companies are addressing complex medical challenges. The company's work in EEG and ablation technologies could influence standards of care for neurological conditions, potentially reducing hospital stays and improving quality of life for patients. For more information about NeuroOne, visit https://www.nmtc1.com. The original press release is available on https://www.newmediawire.com.
The upcoming financial report will provide a snapshot of NeuroOne's performance in a competitive and rapidly evolving sector. As medical technology continues to advance, companies like NeuroOne play a crucial role in translating innovation into practical healthcare solutions. The results may reflect the company's ability to navigate regulatory landscapes, secure partnerships, and drive adoption of its technologies, all of which are critical factors for long-term success in the healthcare industry.
